Global Roundup: EU Approves ViiV’s HIV-1 Drug and More
The Pharma Data
DECEMBER 23, 2020
The agreement includes a £500,000 upfront payment to Avacta which gives Astrea the rights to generate and develop Affimer reagents in-house for affinity separation. In July, ViiV Healthcare, which is based in London, resubmitted the New Drug Application (NDA) for once-monthly dosing of cabotegravir and rilpivirine to the U.S.
Let's personalize your content